OGN Organon & Co.
OGN Organon & Co.
Healthcare · Drug Manufacturers - General
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 bull converging
POC $13.32 · VWAP $10.08 · +36.5% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
OGN Price Structure
Loading timeframes…
Peers
Every watchlist OGN belongs to, members best 30-day change first — OGN highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: revenue $1.56B, diluted EPS $0.40, net income $108M (SEC filing). Across the print the stock moved +0.1% (close before → first close after).
full note →Against street estimates
How OGN's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about OGN from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled today · Oct 17
- Organon Reports Q1 2026 Results Amid Sun Pharma Merger | OGN News & Analysis
- Rockford Register Star: Local News, Politics & Sports in Rockford, IL - Organon & Co. Common Stock (NYSE:OGN) Stock Quote
- Organon posts Q2 2026 results amid Sun Pharma deal | OGN Quarterly Report (10-Q)
- Organon Reports Results for the First Quarter Ended March 31, 2026
- Sun Pharma signs Definitive Agreement to Acquire Organon
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
OGN research tape
43 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.